利用先进子宫内膜模型绘制整倍体与非整倍体人类胚胎的发育及靶向分泌特征
STUDY QUESTION: Do euploid (EU), trisomy 21 (T21), and monosomy 21 (M21) human embryos exhibit different patterns of secreted proteins and morphometric changes during extended in vitro culture, either with or without endometrial cell support? SUMMARY ANSWER: Secreted protein prof…
要点
- CREST子宫内膜支架系统将胚胎活力延长至14天并提高分泌标志物水平。
- 21单体胚胎在CREST中7天即出现hPL、CALR和PlGF分泌减少,且未能扩张。
- 10天时PAPP-A水平可区分整倍体与21三体及21单体胚胎。
核心结论
- 在子宫内膜细胞支持的植入后体外培养中,分泌蛋白谱和形态参数可区分整倍体与非整倍体胚胎。
研究设计与样本
- 采用无细胞培养基和基于细胞工程化容受性子宫内膜支架技术(CREST)的3D培养两种系统,培养至受精后14天。
主要发现
- 无子宫内膜支持的胚胎在10天后的活力受损,β-hCG、hPL、PAPP-A、PlGF和CALR分泌显著减少。
- 无细胞培养基中整倍体和21三体胚胎面积至9天逐渐增加,而21单体胚胎无此变化,但所有胚胎囊胚腔扩张无变化且保持圆形形态。
- CREST系统将活力延长至14天并增强所有评估蛋白标志物的分泌水平。
- CREST中21单体胚胎早在7天即表现出hPL、CALR和PlGF分泌减少;10天时PAPP-A水平可区分整倍体与21三体及21单体胚胎。
- 整倍体胚胎至14天PAPP-A和PlGF逐渐增加,而21三体胚胎无此增加;仅整倍体和21三体胚胎出现植入样扩张、囊胚腔塌陷和轴比增加,21单体胚胎保持圆形且未能扩张。
临床怎么用
- 延长培养中的分泌蛋白分析可作为非侵入性策略,改进超越传统形态学评估的胚胎选择。
- CREST模型可作为转化平台,用于识别新的生殖能力生物标志物并评估改善母胎交流的干预措施。
局限性
- 胚胎数量有限,尽管每种培养条件纳入超过10枚胚胎,生物学变异仍可能影响结果,这与获取纯21号染色体非整倍体胚胎的难度有关。
- CREST系统虽重现子宫内膜关键结构特征,但缺乏内皮和免疫细胞成分,可能影响胚胎发育和植入动态。
- 仅选择了一组靶向分泌蛋白,更广泛的分泌组学方法可提供更全面的表征。
- 发现仅限于纯21号染色体非整倍体,需进一步研究其他染色体非整倍体以评估普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do euploid (EU), trisomy 21 (T21), and monosomy 21 (M21) human embryos exhibit different patterns of secreted proteins and morphometric changes during extended in vitro culture, either with or without endometrial cell support? SUMMARY ANSWER: Secreted protein profiles and morphometric parameters discriminate between euploid and aneuploid embryos during post-implantation in vitro culture with endometrial cell support. WHAT IS KNOWN ALREADY: Extended in vitro culture systems with and without endometrial cells have enabled the study of early human post-implantation development and highlighted the importance of embryo-endometrial crosstalk during implantation. However, how embryo chromosomal status influences implantation dynamics and embryo-endometrial interactions remain poorly understood. STUDY DESIGN, SIZE, DURATION: Laboratory-based study. Sixty-nine supernumerary human embryos donated for research at blastocyst stage (5 days post-fertilization, d.p.f.) (EU, n = 24; T21, n = 21; M21, n = 24) were used. PARTICIPANTS/MATERIALS, SETTING, METHODS: Extended in vitro culture until 14 d.p.f. was performed using two systems: a cell-free culture medium optimized for post-implantation development, and a 3D culture based on cell-engineered receptive endometrial scaffold technology (CREST), providing epithelial and stromal cell support. Secreted levels of CALR (calreticulin), β-hCG, human placental lactogen (hPL), pregnancy-associated plasma protein A (PAPP-A), and placental growth factor (PlGF) were quantified at different developmental time points corresponding to 7, 10, 12, and 14 d.p.f. Embryo morphometric parameters, including area, degree of expansion, axis ratio, and circularity were also measured. MAIN RESULTS AND THE ROLE OF CHANCE: Embryos cultured without endometrial support showed compromised viability beyond 10 d.p.f., with significantly reduced secretion of β-hCG, hPL, PAPP-A, PlGF, and CALR. The area of post-implanted EU and T21 embryos cultured in cell-free medium progressively increased up to 9 d.p.f., unlike M21 embryos. However, all showed no changes in blastocoel expansion and maintained a rounded morphology throughout all post-implantation culture. CREST systems extended viability up to 14 d.p.f. and enhanced secretion levels of all evaluated protein markers compared with embryos cultured in cell-free conditions. Among embryos cultured in CREST systems, M21 embryos exhibited diminished hPL, CALR, and PlGF secretion as early as 7 d.p.f. At 10 d.p.f., PAPP-A levels distinguished EU from both T21 and M21 embryos. Progressive increases in PAPP-A and PlGF were observed in EU embryos until 14 d.p.f., but not in T21 embryos. Morphometric analysis revealed that only EU and T21 embryos underwent implantation-like expansion, blastocoel collapse, and increased axis ratio. In contrast, M21 embryos retained a rounded morphology and failed to expand. LARGE SCALE DATA: No OMIC technique was performed in this research. LIMITATIONS, REASONS FOR CAUTION: One of the main limitations of this study is the number of embryos used. Although more than 10 embryos were included in each culture condition, biological variability may still have influenced the results. This limitation is related to the difficulty of obtaining pure chromosome 21 aneuploid embryos. In addition, while the CREST system successfully recapitulates key structural features of the endometrium, it lacks endothelial and immune cell components, which may influence embryo development and implantation dynamics. Finally, we selected a targeted set of secreted proteins based on their relevance to the main objective of the study; however, the use of broader secretomic approaches could have provided a more comprehensive characterization of embryo-endometrial interactions. The findings are limited to pure chromosome 21 aneuploidies; therefore, further studies including aneuploidies affecting other chromosomes are warranted to assess the generalizability of the results. WIDER IMPLICATIONS OF THE FINDINGS: The obtained results demonstrate the usefulness of the CREST system to study implantation process. Besides, these findings support the potential of secreted proteins analysis in extended culture as a non-invasive strategy to improve embryo selection beyond conventional morphological assessment. In parallel, we establish the CREST model as a translational platform to identify novel reproductive competence biomarkers and evaluate interventions aimed at improving maternal-embryo communication, not only after implantation but also during the pre-implantation phase. FUNDING: This research was funded by the Institute of Health Carlos III (ISCIII) (Spanish Ministry of Science and Innovation) through the FIS program granted to F.D. (PI20/00405, PI23/00860), co-funded by the European Union, the Generalitat Valenciana through the Grant Program for Consolidated Research Groups (CIAICO/2022/203 [F.D.]), Centro para el Desarrollo Tecnológico y la Innovación (CDTI; reference number IDI-20210916) (Spanish Ministry of Science and Innovation) granted to I.S.-R. and Fundación Merck Salud through XXXI Merck Research Grant on Fertility granted to F.D. A.P. and R.Y.-S. are funded by Generalitat Valenciana Grant for the hiring of support staff linked to a technology transfer project (CIAPOT/2022/18 [A.P.]) and training research (CIACIF/2021/051 [R.Y.-S.]). S.M.-A. is funded by Institute of Health Carlos III (ISCIII) (Spanish Ministry of Science and Innovation) through the contract of training research personnel into health (FI24/00068), co-funded by the European Union. M.A.M. was supported by the Stanford Dunlevie Maternal Fetal Medicine Center for Discovery, Innovation and Impact, the Duan Family Faculty Scholar in Maternal-Fetal Medicine, the FY25 ASRM Discovery & Innovation Grant from the American Society for Reproductive Medicine, and the California Institute for Regenerative Medicine (DISC0-17685). DISCLOSURES: Matteo Molè, declares that he serves as an advisory board member and consultant for Opal Therapeutics (CA, USA) and Genie Fertility (UK). He is also a co-inventor of the patent 'A Method of Generating an In Vitro Endometrium Assembloid' (UK Patent No. BAB-C-P3371GBp). All other authors have no financial nor competing interest to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Yagüe-Serrano R, Piñeiro-Silva C, Morales-Álvarez S, et al. Mapping developmental and targeted secretory signatures of euploid and aneuploid human embryos using an advanced endometrial model. Hum Reprod. 2026. PMID: 42927452. doi:10.1093/humrep/deag166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。